

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2012-04-30** | Period of Report: **2012-04-30**
SEC Accession No. [0001193125-12-193852](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

NOVADAQ TECHNOLOGIES INC

CIK: **1173293** | IRS No.: **000000000**

Type: **6-K** | Act: **34** | File No.: **001-35446** | Film No.: **12792263**

SIC: **3845** Electromedical & electrotherapeutic apparatus

Mailing Address

2585 SKYMARK AVENUE

SUITE 306

MISSISSAUGA A6 L4W 4LS

Business Address

2585 SKYMARK AVENUE

SUITE 306

MISSISSAUGA A6 L4W 4LS

905-629-3822

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the month of April 2012

(Commission File No. 001-35446)

NOVADAQ TECHNOLOGIES INC.

(Translation of registrant' s name into English)

2585 Skymark Avenue
Suite 306, Mississauga
Ontario, Canada L4W 4LS

(Address of registrant' s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

NOVADAQ TECHNOLOGIES INC.

(Registrant)

By: /s/ Stephen Purcell

Name: Stephen Purcell

Title: Chief Financial Officer

Date: April 30, 2012

EXHIBIT INDEX

Exhibit

Description

99.1 Press Release

**For Immediate Release****Novadaq to Present at Deutsche Bank 37th Annual Health Care Conference**

Toronto, Ontario – April 30, 2012 - Novadaq[®] Technologies Inc. (“**Novadaq**” or the “**Company**”) (NASDAQ: NVDQ, TSX: NDQ), a developer of real-time medical imaging systems for use in the operating room, today announced that Dr. Arun Menawat, the company’s president and chief executive officer, will present Novadaq’s corporate overview at the Deutsche Bank Securities, Inc. 37th Annual Health Care Conference at 2:10 PM ET on Monday, May 7, 2012, at the InterContinental Boston in Boston, MA.

A webcast of the presentation can be accessed live on the Company’s website at <http://www.novadaq.com> under the “Events” tab in the “Investors” section, and will be archived for 90 days.

About Novadaq Technologies Inc.

Novadaq primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open, minimally invasive or interventional surgical procedures are performed. The Company’s SPY[®] Imaging core technology enables surgeons to visualize blood flow in vessels, co-joined vessels and micro-vessels, and to assess the quality of blood perfusion in tissue, without exposing the patient to radiation. More than 50 peer-reviewed publications demonstrate that the use of SPY Imaging during complex surgery leads to fewer post-operative complications and lower hospital costs. The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use during a variety of open surgical applications. The endoscopic version of SPY, which is branded PINPOINT[®], combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. The majority of Novadaq’s current revenues come from alliances formed with leading companies in relevant markets in which SPY technology has been demonstrated to improve clinical outcomes in open, minimally invasive and robotic surgery applications. Novadaq’s first alliance integrates SPY Imaging into the 3-D HD imaging capabilities of the da Vinci[®] Surgical Robotic System offered by Intuitive Surgical[®], Inc. The integrated system, FIREFLY, received FDA 510(k) clearance in February 2011. In September 2010, Novadaq entered into an exclusive North American sales and marketing alliance with LifeCell[™] Corporation, for SPY in open plastic and reconstructive, gastrointestinal and head and neck surgeries. In November 30, 2011, Novadaq signed exclusive, multi-year sales and marketing agreements with Kinetic Concepts, Inc., for wound care applications and extended its agreement with LifeCell for the commercialization of the SPY System into vascular surgery. In addition, the SPY Imaging System for cardiac applications is marketed directly, whereas the CO2 Heart Laser[™] for TMR is distributed by MAQUET Cardiovascular. For more information, please visit the Company’s website at <http://www.novadaq.com>.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq’s current beliefs

Novadaq to Present at 37th Annual Deutsche Bank Health Care Conference

as well as assumptions made by and information currently available to Novadaq and relate to, among other things, the Company's strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings available at www.sedar.com, actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Relations Contacts

David C. Martin
Vice President, Corporate Development and Investor Relations
Novadaq Technologies Inc.
905-629-3822 ext: 218
dmartin@novadaq.com